临床肿瘤学杂志

• 论著 • 上一篇    下一篇

107例非小细胞肺癌三维适形放疗或联合化疗的疗效及预后因素

艾尼瓦尔·艾木都拉,艾力江·吐尔逊,尚 革,包永星   

  1. 830054 乌鲁木齐新疆医科大学第一附属医院肿瘤中心
  • 收稿日期:2012-01-13 修回日期:2012-05-18 出版日期:2012-11-30 发布日期:2012-11-30
  • 通讯作者: 尚 革

The efficacy and prognosis of threedimensional conformal radiation therapy plus chemotherapy for 107 patients with non-small cell lung cancer

AINIWAER Aimudula,AILIJIANG Tuerxun,SHANG Ge,BAO Yong-xing

  

  1. Department of Oncology, the First Affiliated Hospital, Xinjiang Medical University, Urumqi 830054,China
  • Received:2012-01-13 Revised:2012-05-18 Online:2012-11-30 Published:2012-11-30
  • Contact: SHANG Ge

摘要:

的 观察非小细胞肺癌(NSCLC)应用三维适形放疗(3DCRT)或3DCRT联合化疗的疗效和安全性,并分析影响其预后的因素。方法 将随访资料完整的107例NSCLC患者纳入分析,其中接受单纯3DCRT 26例,3DCRT联合化疗81例。3DCRT剂量2Gy/次,5次/周,中位DT 60Gy。评价近期疗效及毒副反应。应用KaplanMeier法和多因素Cox模型分析全组NSCLC患者的生存预后情况。结果 全组患者获CR 10例(9.3%),PR 56 例(52.3%),SD 30例(28.0%),PD 11例(10.4%),总有效率(RR)为61.7%(66/107)。随访14~62个月,中位随访27个月,随访率为96%。1、3、5年的生存率分别为67%、31%和22%,中位总生存时间(OS)为20.2个月。急性放射性肺炎2级3例,3级2例;晚期放射性肺炎2级1例,3级1例。急性放射性食管炎1级49例,2、3级9例。骨髓抑制1、2级32例,3、4级5例。单因素分析显示,临床分期、KPS评分、肿瘤体积、放疗剂量、治疗模式及近期疗效显著影响OS,而年龄、体重减轻及病理类型对OS无影响。Cox多因素分析显示,临床分期、治疗模式和近期疗效是影响预后的独立因素。结论 3DCRT联合化疗治疗NSCLC的近期疗效较好,毒副反应可耐受;临床分期、治疗模式和近期疗效可能是影响NSCLC预后的因素。

Abstract:

Objective To observe the efficacy and safety of threedimensional conformal radiotherapy (3DCRT) combined with chemotherapy for nonsmall cell lung cancer (NSCLC), and analyze the factors influencing the prognosis of NSCLC patients. Methods One hundred and seven patients who were treated either by radiotherapy alone (26 patients) or radiotherapy plus chemotherapy (81 patients) from Jan. 2005 to Dec. 2008 were entered into the database for analysis. The radiotherapy dose was delivered at 2Gy/fraction, 5 fractions per week. The median total dose was 60Gy. The efficacy and toxicities were evaluated. Kaplan-Meier and Cox model were applied to analyze the survival of NSCLC. Results The response rate after 3DCRT was 61.7%(66/107) with complete remission 9.3% (10/107) and partial remission 52.3% (56/107). The median followup time was 27 months, and 1-, 3-,5-year overall survival rates were 67%,31% and 22%. The median survival time(MST) was 20.2 months. The Logrank test showed clinical stage, KPS performance, tumor volume, radiation dose,treatment regimen and response to treatment were correlated with overall survival. By Cox multivariable regression,the independent adverse prognostic factors were clinical stage, treatment type and response to treatment. Grade 2 acute radiation pneumonitis was observed in 3 patients and grade 3 in 2 patients. Late lung injury developed in 1 patient with grade 2, 1 patient with grade 3. Acute radiation esophagitis was observed in 49 patients with grade 1,above grade 2 developed in 9 patients. Acute grade 1,2 hematologic toxicity developed in 32 patients, above grade 2 developed in 5 patients. Conclusion 3DCRT combined with chemotherapy for NSCLC patients is effective and well tolerated. Clinical stage, treatment type and response to treatment may be the factors influencing the prognosis of NSCLC patients.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!